On This Page

Filter

These are the filters currently being used to limit the search results. Click on the
icon to remove the filter.

answer › grouped question UIN

HL997

max date

2015-07-01

answer › is ministerial correction

false

Sort by

This list shows the properties that you can sort by. Click on to sort in ascending order and to sort in descending order. The properties that you're currently sorting by are
shown at the top of the list. Click on to remove a sort and or to reverse the current sort order. Click on the icon to remove all the sorting. Note that sorting can significantly slow down the
loading of the page.

View

Choose what information you want to view about each item. There are some pre-defined
views, but starred properties are always present no matter what the view. You can
star properties by clicking on the icon. The currently starred icons have a icon; clicking on it will unstar the property.

To ask Her Majesty’s Government whether they will place in the Library of the House
any publications resulting from the phase 3 clinical trials approved for the potential
treatment of systemic amyloidosis or multiple myeloma; and what is the National Institute
of Health Research’s assessment of progress in these areas.

<p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’
in the United Kingdom. These are being conducted by two commercial sponsors, Millennium
Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial
sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors
are required to publish a summary of their trial results to the EU Clinical Trials
Register within one year of their trial completing. At that point, these results will
become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p>
</p><p>The Department of Health, which funds the National Institute for Health Research
(NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical
Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay
representatives to coordinate development of a strategic portfolio of trials within
their field. All CSGs interact with clinical research networks, funders (including
NIHR) and researchers to develop studies aimed at improving outcomes for patients.
The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report
that includes an assessment of progress in these areas is attached and available on
the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf"
target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p>
</p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results
are known, the commercial potential of these trial’s products will be a matter for
the respective trial sponsors.</p><p> </p>

To ask Her Majesty’s Government whether there are currently any trials for systemic
amyloidosis in humans being conducted by the National Institute of Health Research
charities or the commercial sector.

<p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’
in the United Kingdom. These are being conducted by two commercial sponsors, Millennium
Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial
sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors
are required to publish a summary of their trial results to the EU Clinical Trials
Register within one year of their trial completing. At that point, these results will
become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p>
</p><p>The Department of Health, which funds the National Institute for Health Research
(NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical
Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay
representatives to coordinate development of a strategic portfolio of trials within
their field. All CSGs interact with clinical research networks, funders (including
NIHR) and researchers to develop studies aimed at improving outcomes for patients.
The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report
that includes an assessment of progress in these areas is attached and available on
the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf"
target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p>
</p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results
are known, the commercial potential of these trial’s products will be a matter for
the respective trial sponsors.</p><p> </p>